By Meghan McCarthy, CQ Staff
No matter who wins November's presidential election, biotech drug manufacturers are unlikely to get the 14-year period of data exclusivity they seek as part of follow-on biologics drug legislation, according to the candidates' top health policy advisers.
At an annual generics industry conference last week hosted by the Generic Pharmaceutical Association (GPhA), Douglas Holtz-Eakin, adviser to GOP nominee John McCain , and Dora Hughes, senior health adviser to Democratic nominee Barack Obama , said both candidates support the shortest time period possible.
Continue reading Obama, McCain Agree on Speeding Generic Medicines to Market .
![[RSS]](http://67.192.49.194/templates/images/rss_icon.gif){kind=icon}
